Chemokines, Chemokine Receptors and Atherosclerosis

Current Topics in Membranes

Volumn 55, Issue , 2005, Pages 223-253

  John, Alison E ^a   Channon, Keith M ^b   Greaves, David R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645882941     PISSN: 10635823     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1063-5823(04)55009-3     Document Type: Review

References (166)

1. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., Hartmann D., Sedlacek R., Dietrich S., Muetze B., Schuster B., Kallen K.J., Saftig P., Rose-John S., and Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J. Immunol. 172 (2004) 6362-6372
2. Abi-Younes S., Sauty A., Mach F., Sukhova G.K., Libby P., and Luster A.D. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 86 (2000) 131-138
3. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Natoli E., Rollins B.J., and Milos P.M. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb. Vasc. Biol. 19 (1999) 1518-1525
4. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3 (2003) 36-50
5. Alcami A., and Koszinowski U.H. Viral mechanisms of immune evasion. Immunol. Today 21 (2000) 447-455
6. Alcami A., Symons J.A., Collins P.D., Williams T.J., and Smith G.L. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160 (1998) 624-633
7. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96 (1999) 5698-5703
8. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., and Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
9. Berger O., Gan X., Gujuluva C., Burns A.R., Sulur G., Stins M., Way D., Witte M., Weinand M., Said J., Kim K.S., Taub D., Graves M.C., and Fiala M. CXC and CC chemokine receptors on coronary and brain endothelia. Mol. Med. 5 (1999) 795-805
10. Berkhout T.A., Sarau H.M., Moores K., White J.R., Elshourbagy N., Appelbaum E., Reape R.J., Brawner M., Makwana J., Foley J.J., Schmidt D.B., Imburgia C., McNulty D., Matthews J., O'Donnell K., O'Shannessy D., Scott M., Groot P.H., and Macphee C. Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B. J. Biol. Chem. 272 (1997) 16404-16413
11. Bernstein L.R., Antoniades H., and Zetter B.R. Migration of cultured vascular cells in response to plasma and platelet-derived factors. J. Cell Sci. 56 (1982) 71-82
12. Bertini R., Allegretti M., Bizzarri C., Moriconi A., Locati M., Zampella G., Cervellera M.N., Di Cioccio V., Cesta M.C., Galliera E., Martinez F.O., Di Bitondo R., Troiani G., Sabbatini V., D'Anniballe G., Anacardio R., Cutrin J.C., Cavalieri B., Mainiero F., Strippoli R., Villa P., Di Girolamo M., Martin F., Gentile M., Santoni A., Corda D., Poli G., Mantovani A., Ghezzi P., and Colotta F. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA 101 (2004) 11791-11796
13. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol. Ther. 79 (1998) 205-230
14. Blaha M., Krejsek J., Blaha V., Andrys J., Vokurkova D., Maly J., Blazek M., and Skorepova M. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol. Res. 53 (2004) 273-278
15. Boisvert W.A., Santiago R., Curtiss L.K., and Terkeltaub R.A. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101 (1998) 353-363
16. Bonville C.A., Lau V.K., DeLeon J.M., Gao J.L., Easton A.J., Rosenberg H.F., and Domachowske J.B. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol. 78 (2004) 7984-7989
17. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
18. Burke-Gaffney A., Brooks A.V., and Bogle R.G. Regulation of chemokine expression in atherosclerosis. Vascul. Pharmacol. 38 (2002) 283-292
19. Burns J.M., Dairaghi D.J., Deitz M., Tsang M., and Schall T.J. Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J. Biol. Chem. 277 (2002) 2785-2789
20. Bursill C.A., Cai S., Channon K.M., and Greaves D.R. Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo. Immunobiology 207 (2003) 187-196
21. Bursill C., Choudhury R., Ali Z., and Greaves D.R. Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and athersclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 110 (2004) 2460-2466
22. Bustos C., Hernandez-Presa M.A., Ortego M., Tunon J., Ortega L., Perez F., Diaz C., Hernandez G., and Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32 (1998) 2057-2064
23. Carfi A., Smith C.A., Smolak P.J., McGrew J., and Wiley D.C. Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc. Natl. Acad. Sci. USA 96 (1999) 12379-12383
24. Chandrasekar B., Bysani S., and Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J. Biol. Chem. 279 (2004) 3188-3196
25. Chen Z., Ishibashi S., Perrey S., Osuga Ji., Gotoda T., Kitamine T., Tamura Y., Okazaki H., Yahagi N., Iizuka Y., Shionoiri F., Ohashi K., Harada K., Shimano H., Nagai R., and Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb. Vasc. Biol. 21 (2001) 372-377
26. Chuntharapai A., Lee J., Hebert C.A., and Kim K.J. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J. Immunol. 153 (1994) 5682-5688
27. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh W.A., and Law R.E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb. Vasc. Biol. 21 (2001) 365-371
28. Combadiere C., Potteaux S., Gao J.L., Esposito B., Casanova S., Lee E.J., Debre P., Tedgui A., Murphy P.M., and Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
29. Cullen P., Baetta R., Bellosta S., Bernini F., Chinetti G., Cignarella A., von Eckardstein A., Exley A., Goddard M., Hofker M., Hurt-Camejo E., Kanters E., Kovanen P., Lorkowski S., McPheat W., Pentikainen M., Rauterberg J., Ritchie A., Staels B., Weitkamp B., and de Winther M. MAFAPS Consortium. Rupture of the atherosclerotic plaque: does a good animal model exist?. Arterioscler Thromb. Vasc. Biol. 23 (2003) 535-542
30. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., Gerrity R., Schwartz C.J., and Fogelman A.M. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA 87 (1990) 5134-5138
31. D'Ambrosio D., Panina-Bordignon P., and Sinigaglia F. Chemokine receptors in inflammation: An overview. J. Immunol. Methods 273 (2003) 3-13
32. Dansky H.M., Charlton S.A., Harper M.M., and Smith J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA 94 (1997) 4642-4646
33. Daugherty A., Pure E., Delfel-Butteiger D., Chen S., Leferovich J., Roselaar S.E., and Rader D.J. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J. Clin. Invest. 100 (1997) 1575-1580
34. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94 (1996) 2013-2020
35. Dawson T.C., Kuziel W.A., Osahar T.A., and Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143 (1999) 205-211
36. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol. Pharmacol. 57 (2000) 833-839
37. Diomede L., Albani D., Sottocorno M., Donati M.B., Bianchi M., Fruscella P., and Salmona M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb. Vasc. Biol. 21 (2001) 1327-1332
38. Faggiotto A., Ross R., and Harker L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4 (1984) 323-340
39. Feldmann M., Maini R.N., Bondeson J., Taylor P., Foxwell B.M., and Brennan F.M. Cytokine blockade in rheumatoid arthritis. Adv. Exp. Med. Biol. 490 (2001) 119-127
40. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., and Patel D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188 (1998) 1413-1419
41. Foxwell B., Andreakos E., Brennan F., Feldmann M., Smith C., and Conron M. Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann. Rheum. Dis. 62 Suppl 2. (2003) ii90-ii93
42. Frostegard J., Haegerstrand A., Gidlund M., and Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 90 (1991) 119-126
43. Gerard C., and Rollins B.J. Chemokines and disease. Nat. Immunol. 2 (2001) 108-115
44. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., Yoshida M., Ding H.A., Gimbrone Jr. M.A., Luster A.D., Luscinskas F.W., and Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999) 718-723
45. Gimbrone Jr. M.A., Topper J.N., Nagel T., Anderson K.R., and Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. New York Acad. Sci. 902 (2000) 230-240
46. Gladue R.P., Tylaska L.A., Brissette W.H., Lira P.D., Kath J.C., Poss C.S., Brown M.F., Paradis T.J., Conklyn M.J., Ogborne K.T., McGlynn M.A., Lillie B.M., DiRico A.P., Mairs E.N., McElroy E.B., Martin W.H., Stock I.A., Shepard R.M., Showell H.J., and Neote K. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. 278 (2003) 40473-40480
47. Gong J.H., Ratkay L.G., Waterfield J.D., and Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186 (1997) 131-137
48. Gonzalo J.A., Lloyd C.M., Wen D., Albar J.P., Wells T.N., Proudfoot A., Martinez-A C., Dorf M., Bjerke T., Coyle A.J., and Gutierrez-Ramos J.C. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188 (1998) 157-167
49. Gough P.J., Greaves D.R., Suzuki H., Hakkinen T., Hiltunen M.O., Turunen M., Herttuala S.Y., Kodama T., and Gordon S. Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler Thromb. Vasc. Biol. 19 (1999) 461-471
50. Greaves D.R., Hakkinen T., Lucas A.D., Liddiard K., Jones E., Quinn C.M., Senaratne J., Green F.R., Tyson K., Boyle J., Shanahan C., Weissberg P.L., Gordon S., and Yla-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb. Vasc. Biol. 21 (2001) 923-929
51. Grosskreutz C.L., Anand-Apte B., Duplaa C., Quinn T.P., Terman B.I., Zetter B., and D'Amore P.A. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc. Res. 58 (1999) 128-136
52. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., and Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2 (1998) 275-281
53. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., and Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99 (1997) 2752-2761
54. Haley K.J., Lilly C.M., Yang J.H., Feng Y., Kennedy S.P., Turi T.G., Thompson J.F., Sukhova G.H., Libby P., and Lee R.T. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: Using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102 (2000) 2185-2189
55. Han K.H., and Quehenberger O. Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins. Trends. Cardiovasc. Med. 10 (2000) 209-216
56. Han K.H., Chang M.K., Boullier A., Green S.R., Li A., Glass C.K., and Quehenberger O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J. Clin. Invest. 106 (2000) 793-802
57. Han K.H., Tangirala R.K., Green S.R., and Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb. Vasc. Biol. 18 (1998) 1983-1991
58. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1876-1890
59. Haque N.S., Fallon J.T., Pan J.J., Taubman M.B., and Harpel P.C. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood 103 (2004) 1296-1304
60. Haque N.S., Zhang X., French D.L., Li J., Poon M., Fallon J.T., Gabel B.R., Taubman M.B., Koschinsky M., and Harpel P.C. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 102 (2000) 786-792
61. Harada A., Sekido N., Akahoshi T., Wada T., Mukaida N., and Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J. Leukoc. Biol. 56 (1994) 559-564
62. Haringman J.J., Kraan M.C., Smeets T.J., Zwinderman K.H., and Tak P.P. Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62 (2003) 715-721
63. Harrison J.K., Jiang Y., Wees E.A., Salafranca M.N., Liang H.X., Feng L., and Belardinelli L. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J. Leukoc. Biol. 66 (1999) 937-944
64. Haskell C.A., Cleary M.D., and Charo I.F. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J. Biol. Chem. 274 (1999) 10053-10058
65. Hayes I.M., Jordan N.J., Towers S., Smith G., Paterson J.R., Earnshaw J.J., Roach A.G., Westwick J., and Williams R.J. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb. Vasc. Biol. 18 (1998) 397-403
66. Hofnagel O., Luechtenborg B., Plenz G., and Robenek H. Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler Thromb. Vasc. Biol. 22 (2002) 710-711
67. Horvath C., Welt F.G., Nedelman M., Rao P., and Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: Inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. 90 (2002) 488-494
68. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., Gudas J.M., and Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161 (2002) 125-134
69. Huffnagle G.B., McNeil L.K., McDonald R.A., Murphy J.W., Toews G.B., Maeda N., and Kuziel W.A. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163 (1999) 4642-4646
70. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., Littman D.R., Weber C., and Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 9 (2003) 61-67
71. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., and Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (1997) 521-530
72. Inoue S., Egashira K., Ni W., Kitamoto S., Usui M., Otani K., Ishibashi M., Hiasa K., Nishida K., and Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106 (2002) 2700-2706
73. Ishibashi M., Egashira K., Hiasa K., Inoue S., Ni W., Zhao Q., Usui M., Kitamoto S., Ichiki T., and Takeshita A. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40 (2002) 687-693
74. Ishibashi M., Hiasa K., Zhao Q., Inoue S., Ohtani K., Kitamoto S., Tsuchihashi M., Sugaya T., Charo I.F., Kura S., Tsuzuki T., Ishibashi T., Takeshita A., and Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ. Res. 94 (2004) 1203-1210
75. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., and Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92 (1993) 883-893
76. Ito T., Ikeda U., Yamamoto K., and Shimada K. Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 165 (2002) 51-55
77. John A.E., and Lukacs N.W. Chemokines and asthma. Sarcoidosis Vasc. Diffuse. Lung. Dis. 20 (2003) 180-189
78. Jonasson L., Holm J., Skalli O., Bondjers G., and Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6 (1986) 131-138
79. Kaartinen M., Penttila A., and Kovanen P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90 (1994) 1669-1678
80. Kinlay S., Libby P., and Ganz P. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 12 (2001) 383-389
81. Knowles J.W., and Maeda N. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb. Vasc. Biol. 20 (2000) 2336-2345
82. Korzenik J.R. Crohn's disease: Future anti-tumor necrosis factor therapies beyond infliximab. Gastroenterol Clin. North Am 33 ix (2004) 285-301
83. Kovanen P.T., Kaartinen M., and Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92 (1995) 1084-1088
84. Kuziel W.A., Dawson T.C., Quinones M., Garavito E., Chenaux G., Ahuja S.S., Reddick R.L., and Maeda N. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167 (2003) 25-32
85. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., and Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101 (2000) 1311-1318
86. Lesnik P., Haskell C.A., and Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111 (2003) 333-340
87. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8 (2002) 1235-1242
88. Liang M., Mallari C., Rosser M., Ng H.P., May K., Monahan S., Bauman J.G., Islam I., Ghannam A., Buckman B., Shaw K., Wei G.P., Xu W., Zhao Z., Ho E., Shen J., Oanh H., Subramanyam B., Vergona R., Taub D., Dunning L., Harvey S., Snider R.M., Hesselgesser J., Morrissey M.M., and Perez H.D. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem. 275 (2000) 19000-19008
89. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
90. Lord R.S., and Bobryshev Y.V. Hallmarks of atherosclerotic lesion development with special reference to immune inflammatory mechanisms. Cardiovasc. Surg. 10 (2002) 405-414
91. Lucas A.D., Bursill C., Guzik T.J., Sadowski J., Channon K.M., and Greaves D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108 (2003) 2498-2504
92. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., and Luster A.D. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104 (1999) 1041-1050
93. Mack M., Cihak J., Simonis C., Luckow B., Proudfoot A.E., Plachy J., Bruhl H., Frink M., Anders H.J., Vielhauer V., Pfirstinger J., Stangassinger M., and Schlondorff D. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166 (2001) 4697-4704
94. Martinez-Gonzalez J., Alfon J., Berrozpe M., and Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159 (2001) 27-33
95. Matloubian M., David A., Engel S., Ryan J.E., and Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1 (2000) 298-304
96. McDermott D.H., Halcox J.P., Schenke W.H., Waclawiw M.A., Merrell M.N., Epstein N., Quyyumi A.A., and Murphy P.M. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 89 (2001) 401-407
97. Minami M., Kume N., Shimaoka T., Kataoka H., Hayashida K., Akiyama Y., Nagata I., Ando K., Nobuyoshi M., Hanyuu M., Komeda M., Yonehara S., and Kita T. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb. Vasc. Biol. 21 (2001) 1796-1800
98. Mirzadegan T., Diehl F., Ebi B., Bhakta S., Polsky I., McCarley D., Mulkins M., Weatherhead G.S., Lapierre J.M., Dankwardt J., Morgans Jr. D., Wilhelm R., and Jarnagin K. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: Binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275 (2000) 25562-25571
99. Mitani H., Egashira K., and Kimura M. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol. Res. 48 (2003) 417-427
100. Moatti D., Faure S., Fumeron F., Amara MelW., Seknadji P., McDermott D.H., Debre P., Aumont M.C., Murphy P.M., de Prost D., and Combadiere C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 (2001) 1925-1928
101. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., and Fallon J.T. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90 (1994) 775-778
102. Moser B., Barella L., Mattei S., Schumacher C., Boulay F., Colombo M.P., and Baggiolini M. Expression of transcripts for two interleukin-8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem. J. 294 (Pt 1) (1993) 285-292
103. Napoli C., D'Armiento F.P., Mancini F.P., Postiglione A., Witztum J.L., Palumbo G., and Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 100 (1997) 2680-2690
104. Nelken N.A., Coughlin S.R., Gordon D., and Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 88 (1991) 1121-1127
105. Ness T.L., Hogaboam C.M., Strieter R.M., and Kunkel S.L. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J. Immunol. 171 (2003) 3775-3784
106. Ng H.P., May K., Bauman J.G., Ghannam A., Islam I., Liang M., Horuk R., Hesselgesser J., Snider R.M., Perez H.D., and Morrissey M.M. Discovery of novel non-peptide CCR1 receptor antagonists. J. Med. Chem. 42 (1999) 4680-4694
107. Ni W., Egashira K., Kitamoto S., Kataoka C., Koyanagi M., Inoue S., Imaizumi K., Akiyama C., Nishida K.I., and Takeshita A. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103 (2001) 2096-2101
108. Okopien B., Haberka M., Cwalina L., Kowalski J., Belowski D., Madej A., Zielinski M., Krysiak R., Labuzek K., Kalina Z., and Herman Z.S. Plasma cytokines as predictors of coronary heart disease. Res. Commun. Mol. Pathol. Pharmacol. 112 (2002) 5-15
109. Osterud B., and Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 83 (2003) 1069-1112
110. Parissis J.T., Adamopoulos S., Venetsanou K.F., Mentzikof D.G., Karas S.M., and Kremastinos D.T. Serum profiles of C-C chemokines in acute myocardial infarction: Possible implication in postinfarction left ventricular remodeling. J. Interferon. Cytokine. Res. 22 (2002) 223-229
111. Parry C.M., Simas J.P., Smith V.P., Stewart C.A., Minson A.C., Efstathiou S., and Alcami A. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med. 191 (2000) 573-578
112. Pasceri V., Cheng J.S., Willerson J.T., Yeh E.T., and Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
113. Pattison J.M., Nelson P.J., Huie P., Sibley R.K., and Krensky A.M. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant 15 (1996) 1194-1199
114. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., and Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA 89 (1992) 4471-4475
115. Plater-Zyberk C., Hoogewerf A.J., Proudfoot A.E., Power C.A., and Wells T.N. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. 57 (1997) 117-120
116. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M., and Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
117. Podolin P.L., Bolognese B.J., Foley J.J., Schmidt D.B., Buckley P.T., Widdowson K.L., Jin Q., White J.R., Lee J.M., Goodman R.B., Hagen T.R., Kajikawa O., Marshall L.A., Hay D.W., and Sarau H.M. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Immunol. 169 (2002) 6435-6444
118. Proudfoot A.E., Power C.A., Hoogewerf A.J., Montjovent M.O., Borlat F., Offord R.E., and Wells T.N. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271 (1996) 2599-2603
119. Proudfoot A.E., Power C.A., and Wells T.N. The strategy of blocking the chemokine system to combat disease. Immunol. Rev. 177 (2000) 246-256
120. Pyo R., Jensen K.K., Wiekowski M.T., Manfra D., Alcami A., Taubman M.B., and Lira S.A. Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. Am. J. Pathol. 164 (2004) 2289-2297
121. Rasmussen L.M., Hansen P.R., Nabipour M.T., Olesen P., Kristiansen M.T., and Ledet T. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J. 360 (2001) 363-370
122. Reape T.J., and Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 147 (1999) 213-225
123. Reape T.J., Rayner K., Manning C.D., Gee A.N., Barnette M.S., Burnand K.G., and Groot P.H. Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. Am. J. Pathol. 154 (1999) 365-374
124. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., Kashanipour A., Minar E., and Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb. Vasc. Biol. 22 (2002) 1194-1199
125. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., and Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 95 (1998) 7614-7619
126. Romano S.J., and Slee D.H. Targeting selectins for the treatment of respiratory diseases. Curr. Opin. Investig. Drugs 2 (2001) 907-913
127. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
128. Rottman J.B., Ganley K.P., Williams K., Wu L., Mackay C.R., and Ringler D.J. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151 (1997) 1341-1351
129. Schecter A.D., Berman A.B., and Taubman M.B. Chemokine receptors in vascular smooth muscle. Microcirculation 10 (2003) 265-272
130. Schecter A.D., Calderon T.M., Berman A.B., McManus C.M., Fallon J.T., Rossikhina M., Zhao W., Christ G., Berman J.W., and Taubman M.B. Human vascular smooth muscle cells possess functional CCR5. J. Biol. Chem. 275 (2000) 5466-5471
131. Schonbeck U., and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents?. Circulation 109 (2004) II18-II26
132. Schwartz D., Andalibi A., Chaverri-Almada L., Berliner J.A., Kirchgessner T., Fang Z.T., Tekamp-Olson P., Lusis A.J., Gallegos C., and Fogelman A.M. Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J. Clin. Invest. 94 (1994) 1968-1973
133. Shashkin P., Simpson D., Mishin V., Chesnutt B., and Ley K. Expression of CXCL16 in human T cells. Arterioscler Thromb. Vasc. Biol. 23 (2003) 148-149
134. Sheikine Y., and Hansson G.K. Chemokines and atherosclerosis. Ann. Med. 36 (2004) 98-118
135. Shimaoka T., Kume N., Minami M., Hayashida K., Kataoka H., Kita T., and Yonehara S. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 275 (2000) 40663-40666
136. Smith C.A., Smith T.D., Smolak P.J., Friend D., Hagen H., Gerhart M., Park L., Pickup D.J., Torrance D., Mohler K., Schooley K., and Goodwin R.G. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 236 (1997) 316-327
137. Smith J.D., and Breslow J.L. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J. Intern. Med. 242 (1997) 99-109
138. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull Jr. W., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., and Wissler R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89 (1994) 2462-2478
139. Stemme S., Holm J., and Hansson G.K. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb. 12 (1992) 206-211
140. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., McCombie S., Cox K., Fawzi A.B., Chou C.C., Pugliese-Sivo C., Davies L., Moreno M.E., Ho D.D., Trkola A., Stoddart C.A., Moore J.P., Reyes G.R., and Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 12718-12723
141. Sueyoshi S., Yamada T., Niihasi M., Kusumi Y., Oinuma T., Esumi M., Tsuru K., Imai S., Nemoto N., Sakura I., and Mitsumata M. Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis. Ann. New York Acad. Sci. 947 (2001) 429-432
142. Szalai C., Duba J., Prohaszka Z., Kalina A., Szabo T., Nagy B., Horvath L., and Csaszar A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158 (2001) 233-239
143. Tabata T., Mine S., Kawahara C., Okada Y., and Tanaka Y. Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem. Biophys. Res. Commun. 305 (2003) 380-385
144. Takeya M., Yoshimura T., Leonard E.J., and Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum. Pathol. 24 (1993) 534-539
145. Taub D.D., Lloyd A.R., Conlon K., Wang J.M., Ortaldo J.R., Harada A., Matsushima K., Kelvin D.J., and Oppenheim J.J. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177 (1993) 1809-1814
146. Tsou C.L., Haskell C.A., and Charo I.F. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 276 (2001) 44622-44626
147. van Berkel V., Barrett J., Tiffany H.L., Fremont D.H., Murphy P.M., McFadden G., Speck S.H., and Virgin IV H.W. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 74 (2000) 6741-6747
148. Veillard N.R., Kwak B., Pelli G., Mulhaupt F., James R.W., Proudfoot A.E., and Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 94 (2004) 253-261
149. von Hundelshausen P., Weber K.S., Huo Y., Proudfoot A.E., Nelson P.J., Ley K., and Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103 (2001) 1772-1777
150. Wang N., Tabas I., Winchester R., Ravalli S., Rabbani L.E., and Tall A. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J. Biol. Chem. 271 (1996) 8837-8842
151. Wang X., Yue T.L., Ohlstein E.H., Sung C.P., and Feuerstein G.Z. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J. Biol. Chem. 271 (1996) 24286-24293
152. Weber C., Erl W., Weber K.S., and Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30 (1997) 1212-1217
153. Weber C., Schober A., and Zernecke A. Chemokines. Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease. Arterioscler Thromb. Vasc. Biol. 24 (2004) 1997-2008
154. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
155. White J.R., Lee J.M., Young P.R., Hertzberg R.P., Jurewicz A.J., Chaikin M.A., Widdowson K., Foley J.J., Martin L.D., Griswold D.E., and Sarau H.M. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273 (1998) 10095-10098
156. Whitman S.C., Rateri D.L., Szilvassy S.J., Yokoyama W., and Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb. Vasc. Biol. 24 (2004) 1049-1054
157. Widdowson K.L., Elliott J.D., Veber D.F., Nie H., Rutledge M.C., McCleland B.W., Xiang J.N., Jurewicz A.J., Hertzberg R.P., Foley J.J., Griswold D.E., Martin L., Lee J.M., White J.R., and Sarau H.M. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J. Med. Chem. 47 (2004) 1319-1321
158. Wilcox J.N., Nelken N.A., Coughlin S.R., Gordon D., and Schall T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler Thromb. 1 Suppl. 1 (1994) S10-S13
159. Wong B.W., Wong D., and McManus B.M. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc. Pathol. 11 (2002) 332-338
160. Wuttge D.M., Zhou X., Sheikine Y., Wagsater D., Stemme V., Hedin U., Stemme S., Hansson G.K., and Sirsjo A. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb. Vasc. Biol. 24 (2004) 750-755
161. Xie J.H., Nomura N., Lu M., Chen S.L., Koch G.E., Weng Y., Rosa R., Di Salvo J., Mudgett J., Peterson L.B., Wicker L.S., and DeMartino J.A. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J. Leukoc. Biol. 73 (2003) 771-780
162. Yang X.D., Corvalan J.R., Wang P., Roy C.M., and Davis C.G. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. 66 (1999) 401-410
163. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., Sarkioja T., Yoshimura T., Leonard E.J., Witztum J.L., and Steinberg D. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 88 (1991) 5252-5256
164. Yokoya K., Takatsu H., Suzuki T., Hosokawa H., Ojio S., Matsubara T., Tanaka T., Watanabe S., Morita N., Nishigaki K., Takemura G., Noda T., Minatoguchi S., and Fujiwara H. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. Circulation 100 (1999) 903-909
165. Zhou X., Nicoletti A., Elhage R., and Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102 (2000) 2919-2922
166. Zhou Y., Kurihara T., Ryseck R.P., Yang Y., Ryan C., Loy J., Warr G., and Bravo R. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160 (1998) 4018-4025